Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations
Language English Country Great Britain, England Media print-electronic
Document type Letter
Grant support
00023736
Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic)
492222
Grantová Agentura, Univerzita Karlova (Charles University Grant Agency)
PubMed
38615117
PubMed Central
PMC11147753
DOI
10.1038/s41375-024-02248-0
PII: 10.1038/s41375-024-02248-0
Knihovny.cz E-resources
- MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- Blast Crisis * genetics drug therapy pathology MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive * drug therapy genetics pathology MeSH
- Imidazoles * therapeutic use administration & dosage MeSH
- Protein Kinase Inhibitors therapeutic use pharmacology MeSH
- Humans MeSH
- Mutation * MeSH
- Mice MeSH
- Niacinamide analogs & derivatives MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Pyrazoles MeSH
- Pyridazines * therapeutic use administration & dosage MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Letter MeSH
- Names of Substances
- asciminib MeSH Browser
- Fusion Proteins, bcr-abl MeSH
- Imidazoles * MeSH
- Protein Kinase Inhibitors MeSH
- Niacinamide MeSH
- ponatinib MeSH Browser
- Pyrazoles MeSH
- Pyridazines * MeSH
2nd Faculty of Medicine Charles University Prague Czech Republic
Abteilung Hämatologie Onkologie Klinik für Innere Medizin 2 University of Jena Jena Germany
Institute of Hematology and Blood Transfusion Prague Czech Republic
See more in PubMed
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33:1835–50. PubMed PMC
Ochi Y, Yoshida K, Huang YJ, Kuo MC, Nannya Y, Sasaki K, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun. 2021;12:2833. PubMed PMC
How J, Venkataraman V, Hobbs GS. Blast and accelerated phase CML: room for improvement. Hematol Am Soc Hematol Educ Program. 2021;2021:122–8. PubMed PMC
Copland M. Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity. Br J Haematol. 2022;199:665–78. PubMed PMC
Bonifacio M, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukemia in advanced phase. Front Oncol. 2019;9:1132. PubMed PMC
Jain P, Kantarjian HM, Gorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123:4391–402. PubMed PMC
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, et al. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. Hematol Oncol. 2021;14:94. PubMed PMC
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N. Engl J Med. 2019;381:2315–26. PubMed PMC
Tomassetti S, Lee J, Qing X. A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib. Clin Case Rep. 2022;10:e6478. PubMed PMC
Gleixner KV, Filik Y, Berger D, Schewzik C, Stefanzl G, Sadovnik I, et al. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. Am J Cancer Res. 2021;11:4470–84. PubMed PMC
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36:431–43. PubMed PMC
Sponseiler I, Bandian AM, Pusic P, Lion T. Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias. Am J Hematol. 2024;99:E9–11. PubMed
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, et al. Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with philadelphia chromosome-positive advanced myeloid leukemias. Acta Haematol. 2020;143:567–73. PubMed PMC
Curik N, Polivkova V, Burda P, Koblihova J, Laznicka A, Kalina T, et al. Somatic mutations in oncogenes are in chronic myeloid leukemia acquired de novo via deregulated base-excision repair and alternative non-homologous end joining. Front Oncol. 2021;11:744373. PubMed PMC
Soverini S, Martelli M, Bavaro L, De Benedittis C, Sica S, Sorà F, et al. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. Leukemia. 2021;35:2102–7. PubMed
O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401–12. PubMed PMC
